<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541891</url>
  </required_header>
  <id_info>
    <org_study_id>COXAVSSY0311FII</org_study_id>
    <secondary_id>PRO-148</secondary_id>
    <nct_id>NCT01541891</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome</brief_title>
  <acronym>PRO-148</acronym>
  <official_title>STUDY TO COMPARATIVE THE EFFICACY AND SAFETY OF PRO-148 OPHTHALMIC SOLUTION VS.SYSTANE® IN THE TREATMENT OF MILD-TO-MODERATE DRY EYE SYNDROME</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of PRO-148 ophthalmic
      solution compared with SYSTANE ® ophthalmic solution for the treatment of signs and symptoms
      of mild-to-moderate dry eye syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 2, randomized, double masked clinical, parallel-group clinical trial to evaluate the
      efficacy and safety of PRO-148 ophthalmic solution compared with SYSTANE ® ophthalmic
      solution for the treatment of signs and symptoms of mild-to-moderate dry eye syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy outcomes measures.</measure>
    <time_frame>During 60 days</time_frame>
    <description>Evaluating of ocular signs, corneal and interpalpebral conjunctival staining ( Fluoroscein and lissamine green staining), schirmer tear test, tear break-up time and ocular surface condition.
Evaluating of symptom of dry eye, OSDI and investigator's evaluation of global response to treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety outcomes measures.</measure>
    <time_frame>During 60 days</time_frame>
    <description>Evaluation of ocular symptoms and signs,visual acuity (VA), biomicroscopy, intraocular pressure (IOP), funduscopy and cup disc-ratio.
Frequency, severity and relationship to study medication of all adverse events occurring during the course of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Arm A PRO 148 Ophthalmic Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B. SYSTANE® Ophthalmic Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-148 Ophthalmic Solution</intervention_name>
    <description>PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.</description>
    <arm_group_label>Arm A PRO 148 Ophthalmic Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator: SYSTANE ® Ophthalmic Solution</intervention_name>
    <description>Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.</description>
    <arm_group_label>Arm B. SYSTANE® Ophthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of mild-to-moderate drye eye syndrome.

          -  Male or female patients.

          -  Patients 18 years of age

        Exclusion Criteria:

          -  Patients with one blind eye.

          -  Visual acuity of 20/40 in any eye

          -  Patients with history of active stage of any other concomitant ocular disease.

          -  Patients taking any medication, topically or by any other route, which could interfere
             with the study's results, in the 3 days prior to trial or until a time period in which
             residual effects could be present.

          -  Contraindications or sensitivity to any component of the study treatments.

          -  Ocular surgery within the past 3 months.

          -  Contact lens users.

          -  Females of childbearing potential )may not participate in the study if any of the
             following conditions exist:

               -  They are pregnant,

               -  They are breastfeeding,

               -  They have a positive urine pregnancy test at screening,

               -  They intend to become pregnant during the study, or

               -  They do not agree to use adequate birth control methods for the duration of the
                  study.

          -  Participation in any studies of investigational drugs within 90 days previous to the
             inclusion.

        Discontinuation criteria:

          -  Patients could be discontinued before the completion of the study because of adverse
             events, pregnancy, protocol violations, lack of efficacy, or administrative reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José F Alaniz-De La O, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antiguo Hospital Civil de Guadalajara &quot;Fray Antonio Alcalde&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura R Saucedo-Rodíguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antiguo Hospital Civil de Guadalajara &quot;Fray Antonio Alcalde&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leopoldo M Baiza-Durán, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research Department. Laboratorios Sophia SA de CV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antiguo Hospital Civil de Guadalajara &quot;Fray Antonio Alcalde&quot;</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <last_update_submitted>February 29, 2012</last_update_submitted>
  <last_update_submitted_qc>February 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PRO-148</keyword>
  <keyword>Dry eye syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 3, 2013</submitted>
    <returned>August 19, 2013</returned>
    <submitted>August 29, 2013</submitted>
    <returned>November 4, 2013</returned>
    <submitted>November 6, 2013</submitted>
    <returned>December 27, 2013</returned>
    <submitted>May 19, 2014</submitted>
    <returned>June 18, 2014</returned>
    <submitted>June 5, 2017</submitted>
    <returned>January 25, 2018</returned>
    <submitted>February 8, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

